A randomized controlled trial of artemotil (β-arteether) in Zambian children with cerebral malaria

P. E. Thuma, G. J. Bhat, G. F. Mabeza, C. Osborne, G. Biemba, G. M. Shakankale, P. A.M. Peeters, B. Oosterhuis, C. B. Lugt, V. R. Gordeuk

Research output: Contribution to journalArticlepeer-review


The efficacy and safety of intramuscular artemotil (ARTECEF®) was compared to intravenous quinine in African children with cerebral malaria. This prospective block randomized open-label study was conducted at two centers in Zambia. Subjects were children aged 0 to 10 years of age with cerebral malaria and a Blantyre Coma Score of 2 or less. Ninety two children were studied; 48 received artemotil and 44 quinine. No significant differences in survival, coma resolution time, neurologic sequelae, parasite clearance time, and fever resolution time were seen between the two regimens. Rates for negative malaria smears one month after therapy were similar in both groups. Artemotil was a well-tolerated drug in the 48 patients in this study. It appears to be at least therapeutically equivalent to quinine for the treatment of pediatric cerebral malaria. It has the advantage of being able to be given intramuscularly once daily for only five days.

Original languageEnglish (US)
Pages (from-to)524-529
Number of pages6
JournalAmerican Journal of Tropical Medicine and Hygiene
Issue number4
StatePublished - 2000

ASJC Scopus subject areas

  • Parasitology
  • Virology
  • Infectious Diseases


Dive into the research topics of 'A randomized controlled trial of artemotil (β-arteether) in Zambian children with cerebral malaria'. Together they form a unique fingerprint.

Cite this